Korean J Urol.  2015 Aug;56(8):580-586. 10.4111/kju.2015.56.8.580.

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy

• Kim KB
• Jo JK
• Ahn S
• Lee S
• Jeong SJ
• Hong SK
• Byun SS
• Lee SE

• KMID: 2164409
• DOI: http://doi.org/10.4111/kju.2015.56.8.580

Abstract

PURPOSE
Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy (ADT) before diagnosis of CRPC. We investigated the clinical efficacy of abiraterone acetate according to the duration of ADT.
MATERIALS AND METHODS
We reviewed the medical records of 20 patients with mCRPC who received abiraterone acetate after failure of docetaxel chemotherapy from May 2012 to March 2014 at Seoul National University Bundang Hospital. Clinical factors including prostate-specific antigen (PSA) nadir level, time to PSA nadir, PSA doubling time, PSA response, and modes of progression (PSA, radiologic, clinical) were analyzed. Disease progression was classified according to the Prostate Cancer Working Group 2 criteria.
RESULTS
The mean age and PSA value of the entire cohort were 76.0+/-7.2 years and 158.8+/-237.9 ng/mL, respectively. The median follow-up duration was 13.4+/-6.7 months. There were no statistically significant differences in clinical characteristics between patients who received abiraterone acetate with ADT duration<35 months and those who received abiraterone acetate with ADT duration> or =35 months. There were also no significant differences in terms of PSA progression-free survival, radiologic progression-free survival, and clinical progression-free survival between patients with ADT duration<35 months and those with ADT duration > or =35 months.
CONCLUSIONS
Although this was a retrospective study with a small sample size, we did not observe any statistically significant differences in the clinical response to abiraterone acetate between mCRPC patients with long ADT duration and those with short ADT duration in terms of disease progression-free survival.

Keyword

Abiraterone; Androgen receptor antagonists; Prostate neoplasms

MeSH Terms

Abiraterone Acetate/administration & dosage
Aged
Aged, 80 and over
Androgen Receptor Antagonists/administration & dosage
Antineoplastic Agents/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Disease Progression
Drug Administration Schedule
Humans
Kallikreins/blood
Male
Neoplasm Metastasis
Prostate-Specific Antigen/blood
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Retrospective Studies
Taxoids/administration & dosage
Treatment Outcome
Abiraterone Acetate
Androgen Receptor Antagonists
Antineoplastic Agents
Kallikreins
Taxoids
Prostate-Specific Antigen

Reference

1. Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol. 2012; 61:950–960. PMID: 22209376.

2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014; 65:467–479. PMID: 24321502.

3. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24:3089–3094. PMID: 16809734.

4. Croke J, Leung E, Segal R, Malone S. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review. BMJ Case Rep. 2012; 11. 01. 2012:pii: bcr2012006540. DOI: 10.1136/bcr-2012-006540.

5. Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013; 24:2402–2408. PMID: 23723295.

6. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008; 8:440–448. PMID: 18674639.

7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364:1995–2005. PMID: 21612468.

8. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368:138–148. PMID: 23228172.

9. Clayton R, Heng DY, Wu JS, Zielinski R, North SA, Emmenegger U, et al. A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2013; 31(Suppl 6):Abstract No. 113.

10. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013; 105:1729–1737. PMID: 24136890.

11. Chi KN, Kheoh TS, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel [abstract]. J Clin Oncol. 2013; 31(Suppl):Abstract No. 5013.

12. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013; 31:2791–2798. PMID: 23816964.

13. Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol. 2015; 67:441–447. PMID: 24508071.

14. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13:983–992. PMID: 22995653.

15. Hofner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, et al. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World J Urol. 2015; 33:833–839. PMID: 25113804.

16. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013; 24:1802–1807. PMID: 23585511.

17. Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res. 2013; 19:3353–3359. PMID: 23470964.

18. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371:1028–1038. PMID: 25184630.